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Background/aim: The objective of the study was to evaluate the response, relapse, reproductive results and demographic features of the
patients with endometrioid adenocancer (EAC) and endometrial intraepithelial neoplasia (EIN) who were treated with conservative
treatment. This is the largest study when we consider the single center studies in this field.
Materials and methods: In the current retrospective study, 38 patients (6 EAC, 31 EIN, 1 synchronous tumors of ovary and endometrium)
were recruited. They were treated with progesterone products for their fertility desire and comorbidity. Reproductive results, response
rates, and recurrence rates were calculated and survival analyses were performed.
Results: Mean duration of the medical treatment was 10 months (range 2–60). Among the 32 patients with EIN, 28 (87.5%) had
a response, 8 (25%) had a relapse and 4 (12.5%) had persistence. Among the 32 patients who expecting fertility, seven patients got
pregnant (21.8%) with a total of five live births. The median follow-up was 40.5 months (range 3–180), and recurrence-free interval was
28.7 months (range 2–180).
Conclusion: Fertility-sparing treatment of EAC and EIN is a feasible approach, and the eligible patients should be given a chance to get
pregnant.
Key words: Fertility-sparing treatment, endometrial cancer, endometrial intraepithelial neoplasia, reproductive outcome, survival

1. Introduction
Endometrial cancer (EC) is the most common
gynecologic cancer whose incidence has increased in the
last few decades, although mortality rates are still low
[1–3]. In women of reproductive age, EC is characterized
by well-differentiated endometrioid adenocarcinoma
at the early stage. It has been reported that this group
of patients have a more favorable prognosis than older
patients [4].
According to the World Health Organization
Classification (2014), endometrial intraepithelial
neoplasia (EIN) is a monoclonal precancerous lesion
with atypical adenomatous hyperplasia, which can
progress to EC with a rate of 29%. It also coexists with
endometrial carcinoma with a rate of 48% [5].
The gold standard and curative therapy for EIN and
EC is hysterectomy, whereas conservative treatment is
optional for preserving fertility or to avoid morbidities or
mortalities of surgery. Conservative treatment consists

of medical treatment with progestins and follow-up
endometrial biopsies every 3–6 months [6–8]. The most
common medical treatment is high-dose oral progestins
such as medroxyprogesterone acetate (MPA), megestrol
acetate (MA), or levonorgestrel-releasing intrauterine
device (LNG-IUD).
The fertility-sparing option takes precedence over
surgical treatment in patients with EIN and EC because
of the increasing number of reproductive-aged women
who postpone childbearing. Fertility-sparing treatment
is a well-accepted approach for patients diagnosed with
endometrial intraepithelial neoplasia and early stage,
grade 1, endometrioid adenocarcinoma (EAC).
This retrospective study aimed to investigate a
single center experience regarding the conservative
management of patients with EIN and EC. We have
analyzed the obstetric and oncologic outcomes after
fertility-sparing treatment of EIN and EAC and also
responses to the treatment.
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2. Materials and methods
In this retrospective study, we recruited 38 patients in the
current study, of which a total of 6 were with EAC, one was
with co-occurrence of the EAC of the ovary and EIN and
31 of all were with EIN. The clinical files of all patients with
EIN/EC who were treated conservatively at the University
of Health Sciences Etlik Zübeyde Hanım Gynecologic
Oncology Clinic were reviewed between March 2005
and May 2020. Eligible patients who were included in
the study were aged between 21 and 88 years old and
had histopathologically confirmed EIN according to the
WHO 2014 Classification of Endometrial Hyperplasias
and Grade 1 EC and Grade 2 EC according to the 2009
International Federation of Obstetrics and Gynaecology
Staging System. The following information was obtained
from the patients’ charts: age, body mass index, parity,
type and duration of infertility, comorbidities, diagnostic
methods, histopathological diagnose, duration and dose
of progestin treatment, presence of complete response or
recurrence, duration of follow-up, method of conception.
All of the patients were fastidiously informed about the
risks of the existing disease and conservative treatment.
The study was performed with the permission of the
Training Plan and Coordination Board Committee of our
institution (18/06/2019- No: 10).
Patients were divided into three groups according
to their histopathological results: EIN, EAC Grade 1,
and EAC Grade 2. First diagnosis was determined with
endometrial tissue sampling by probe curettage in all
patients. Dilatation curettage (D&C) was then performed
to the patients to not miss out any upstage pathology.
Transvaginal sonography was routinely performed for
the presence of any adnexal masses. In the patients with
a diagnosis of endometrial cancer, magnetic resonance
was performed to identify any extension of endometrioid
adenocarcinoma or myometrial invasion before the
beginning of medical treatment. Medical treatment based
on progestin therapy was used for the initial treatment.
If the disease is progressive, a total hysterectomy with
bilateral salpingo-oophorectomy procedure was strongly
recommended. Complete response was defined as the
absence of disease on follow-up endometrial curettages.
Recurrence was defined as the detection of EC or EIN
during the 3- or 6-months later follow-up endometrial
sampling following an endometrial sample result that
showed disease regression. Time to recurrence was
calculated from the date of complete regression. Persistence
was defined as the presence of the initial pathology on
follow-up endometrial curettages. Live births were defined
as the birth of healthy infants, and its rate was defined as
the ratio of the women who gave birth to healthy infants
divided by the total number of women undergoing
fertility-sparing therapy. After a regression achievement,

patient who desired fertility was directed to the infertility
department.
Statistical data analysis was performed using the
Statistical Package for Social Sciences version 21
(IBM Corp., Armonk, NY, USA). The categorical data
was performed using descriptive statistical methods.
Variations between the unpaired groups were analyzed
using the Mann–Whitney U test. Cox proportional
hazards regression analysis method was used to investigate
the univariate effects of BMI, age, histopathology, response
and relapse on survival. Recurrence free survival (RFS)
rates of the patients were calculated from the date of the
complete response to the date of recurrence, and overall
survival (OS) rates of the patients were calculated from
the date of diagnosis to the date of death or last followup. RFS and OS were estimated by using the Kaplan–Meier
method. All p values <0.05 were considered significant.
3. Results
3.1. Patient characteristics
In the current study, 38 patients who underwent medical
treatment for EIN and EAC were analyzed. The mean age of
the patients that underwent conservative treatment (both
fertility sparing and comorbidities) was 34.78 years (range,
21–88). There were six patients with comorbidities or who
did not have fertility desire. One of them was in late-stage
severe dementia due to Alzheimer’s disease (88 year old
patient), the other had hypophysis tumor (30 year old
patient), and the rest of them did not want to be pregnant
and have hysterectomy because of their young age (23, 33,
34 and 36 years old, respectively). The mean value of the
BMI was 32.85 kg/m2 (range 20–48). In all, 28 (73.6%)
patients were diagnosed via probe curettage, 6 (15.7%)
were diagnosed via hysteroscopy and biopsy, and 4 were
diagnosed via dilatation and curettage (10.5%). In total,
32 (84.2%) patients have been diagnosed with EIN, and,
among these patients, one of them had a co-occurrence of
the EAC of the ovary and EIN. Rest of the patients had a
diagnosis of EAC; 4 (10.5%) had grade 1, and 2 (5.3%) had
grade 2 disease, respectively. The patients’ characteristics,
including medical treatments, are shown in Table 1.
3.2. Evaluation of the treatment
All in all, 33 (86.8%) patients were treated with megestrol
acetate, 3 (7.9%) of them were treated with micronized
progesterone, and 2 (5.3%) patients were treated with
medroxyprogesterone acetate (MPA) at the time of the
initial diagnosis (Table 1). Megestrol acetate was the most
commonly used drug, with a daily dose range of 80–480
mg (mostly 160 mg) and a mean treatment duration of
10.4 months (range 2–60). Micronized progesterone
was the second commonly preferred drug with a dose of
200–400 mg/daily, and treatment durations were 2, 6 and
9 months. MPA was administered in two patients with a
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Table 1. Characteristics of patients who underwent conservative
treatment.
Characteristics

Patients (n = 38)

Age (year)

34.78 (21–88)

BMI (kg/m )
2

32.85 (20–48)

<25

4 (10.5%)

≥25, <30

9 (23.7%)

≥30, <35

11 (28.9%)

≥35, <40

5 (13.2%)

≥40

9 (23.7%)

History of infertility

32

Primary

22 (68.75%)

Secondary

10 (31.25%)

Diagnose tool
D&C

4 (10.5%)

H/S Bx

6 (15.7%)

P/C

28 (73.6%)

Histopathology
EIN

32 (84.2%)

EAC Grade 1

4 (10.5%)

EAC Grade 2

2 (5.3%)

Initial medical treatment
Megestrol acetate

33 (86.8%)

Micronized progesterone

3 (7.9%)

MPA

2 (5.3%)

BMI: body mass index, D&C: dilatation curettage, H/S bx:
hysteroscopic biopsy, P/C: probe curettage, EIN: endometrial
intraepithelial neoplasia, EAC: endometrioid adenocancer, MPA:
medroxyprogesterone acetate.

10mg/daily dose, and the treatment durations were 2 and
12 months, respectively.
One of the patients who have treated with megestrol
acetate changed into Levonorgestrel intrauterine system
(LNG-IUD) because of relapse. Mean duration of the
medical treatment was 10 months (range 2–60). Among
the 32 patients with EIN, 28 (87.5%) had a response, 8
(25%) had a relapse, and 4 (12.5%) had persistence (Table
2). Interestingly, there were 4 patients with persistence and
without response in the EAC G1 group. All of the patients
with EAC G2 have shown response to the treatment except
one patient with a relapse (Table 2).
Among the 32 patients who expected fertility, seven
patients got pregnant (21.8%) with a total of five live births
(Table 2). Only one of them got pregnant with artificial
reproductive techniques, whereas the others got pregnant
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spontaneously/in natural ways. All of the pregnancies were
seen in the EIN group.
The median follow-up was 40.5 months (range 3–180),
and recurrence-free interval was 28.7 months (range
2–180, Figure 1 and Figure 2). According to the Kaplan–
Meier method, the cumulative overall survival rate was
91%, and the cumulative recurrence free survival rate was
62%. Ten patients underwent definitive surgery, whereas
28 patients (73.6%) still have their uterus today. On the
basis of the pathological findings after the surgeries, there
were two patients with advanced endometrioid carcinoma
(stage IIIC2 according to the FIGO 2009) whose initial
pathologies were EAC G1 and EIN (Table 3). Their status
resulted in an exitus. Among the four exitus in our series,
the rest two (EAC G1 and EIN) were caused by uncertain
reasons that are not related to the current disease. One of
these two patients was 88 years old patient who received
megestrol acetate 160 mg for nine months and died at the
end of the nine months because of an uncertain reason.
One patient who underwent a debulking operation
with left salphingo-oophorectomy, pelvic/paraaortic
lymph node dissection, infracolic omentectomy and
endometrial biopsy had an endometrioid type grade 1
ovarian cancer, stage IC2 according to the FIGO 2014
ovarian cancer classification system, co-occurrence of
EAC G1 endometrial biopsy pathology, whereas the initial
pathology was EIN. She is still alive and had a pregnancy
resulting in abortus.
4. Discussion
In the current study, our aim was to analyze the results of
the conservative treatment of the patients with EIN/EAC
who desire fertility or have comorbidities.
Although there are limited data available on prospective
conservative treatments, fertility preserving treatment
in eligible patients with cancerous and precancerous
pathologies is an accepted approach today just because a
great amount of endometrial cancer is characterized by
well differentiated endometrioid carcinoma and at early
stage [4, 9,10].
Progestin treatment is the most well accepted approach
for the conservative treatment, whereas there is no
sufficient evidence to specify the convenient dose and
duration of treatment. Oral progestogens such as MPA and
MA are the most preferable materials, but, besides these,
LNG-IUD is an option for a local effect to the endometrial
tissue [11]. LNG-IUD has been shown as a sufficient and
an influential option for the treatment in some studies
[12,13]. In the present study, megestrol acetate was the
most commonly preferred drug with a range of 80–480 mg
dose, daily (mainly 160 mg).
Fan et al. [14] performed an extensive metaanalysis
that contains 28 study and 619 cases of early stage
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Table 2. Outcome of the treatment according to the histopathologic group.
Histopathology

Response

Relapse

Persistence

Pregnancy

Live birth

EIN (32)

28

8

4

7

5

EAC Grade 1 (4)

0

1

4

0

0

EAC Grade 2 (2)

2

1

0

0

0

Total

30
(total of 38, 78.9 %)

10
(total of 33, 30.3 %)

8
(total of 33, 24.2%)

7
(total of 32, 21.8 %)

5
(total of 32, 15.6%)

Survival Function at mean of covariates
1.0

Cum Survival

0.8
0.6
0.4
0.2
0.0
.00

50.00

100.00
OS

150.00

200.00

Figure 1. Survival analysis of the patients.

endometrial cancer were analyzed to evaluate the efficacy
of conservative treatment. The authors reported that 76.3%
patients showed remission, whereas 30.7% have recurrence
rate. In another metaanalysis, Qin et al. [15] reported that
82.4% of patients showed a response to hormonal therapy
addition with a relapse rate of 25.0%. On the other hand,
according to our study, the response rate and the recurrence
rate were 78.9% and 30.3%, respectively. Similar to the
present study, Kim et al. [16] demonstrated a response rate
of 80% in EC patients treated with progestins.
One of the most important goals of fertility preservation
is to achieve pregnancy. The National Comprehensive
Cancer Network and European Society of Gynaecological
Oncology (ESGO) confirms that fertility sparing
treatment is a safe option for stage IA, grade 1 EC patients
with endometrioid type and which disease is limited to
endometrium [17]. When we look at the literature and
compare the results of the present study, we can see that the
pregnancy rate after complete remission is about 30% [18].
In our study, pregnancy rate and live birth rate were 21.8%
and 15.6%, respectively. Qin et al. reported a pregnancy
rate of 28.8%. The live birth rate of this metaanalysis was

19.6% [15]. The majority of the pregnancies obtained by
assisted reproductive techniques (ART) are opposed to the
current study.
Gonthier et al. defined in a multicenter study that
BMI of 30 kg/m2 or greater was associated with a lower
probability of pregnancy [19]. In our study, 25 of all (65%)
patients had BMI of 30 kg/m2 or greater, so this would be
related to a lower pregnancy rate.
The surgical procedure is another hot point in these
patients after completion of fertility desire. The question
is whether to preserve or not the ovaries in young patients
with EIN or EAC, regarding the surgical approach after the
recurrence. In the present study, one patient who was 25
years old had synchronous ovarian cancer (G1 EA) and
G1 EC of endometrium. In a recent study by Wang et
al., 1 patient had ovarian metastasis, and
Page3 1patients were
found to have synchronous ovarian cancer (G1EA) [1].
However, previous studies proposed that synchronization
of endometrial and ovarian carcinoma does not worsen
the survival and prognostic pattern [19–22].
Women undergoing conservative therapy should
be perplexed about their chances of survival. Park et al.
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Survival Functions
Histopathology
EIN
EC G1
EC G2
EIN-censored
EC G1-censored
EC G2-censored

1.0

Cum Survival

0.8

0.6

0.4

0.2

0.0
.00

50.00

100.00

150.00

200.00

Recurrence-free Survival

Figure 2. Recurrence free survival according to the histopathologic groups.
Table 3. Results and outcomes of the operations.
Initial
pathology

Operation

Postoperative pathology

Stage

Pregnancy

Status

EIN

TAH+BSO

Malignite negative

None

Live birth

Alive

EIN

TAH+BSO

EAC G1

IA

None

Alive

EIN

TAH+BSO

EAC G1

IA

None

Alive

EIN

TAH+BSO

EAC G1

IA

None

Alive

EIN

TAH+BSO

EIN

None

None

Alive

EIN

Left USO+BPPLND
+Omentectomy+ D&C

Endometrioid type Grade 1
ovarian cancer + EAC G1

IC2 Ovarian
cancer+ G1 EAC

None

Alive

EIN

TAH+BSO+BPPLND+Omentectomy

EAC G3

IIIC2

None

Exitus

EAC G1

TAH+BSO

EAC G1

IA

None

Alive

EAC G1

TAH+BSO

EAC G1

IA

None

Alive

EAC G1

TAH+BSO+BPPLND+Omentectomy

EAC G3

IIIC2

None

Exitus

TAH+BSO:Total Abdominal Hysterectomy+Bilateral Salphingo-oophorectomy
USO: Unilateral Salphingo-oophorectomy
BPPLND: Bilateral pelvic-paraaortic lymphadenectomy
EAC G1: Endometrioid Adenocarcinoma Grade 1
EIN: Endometrial Intraepithelial Neoplasia
D&C: Dilatation & Curettage

[9] demonstrated that 85% of patients showed disease
regression with oral progestin treatment within a followup duration of 51 months (range, 24–160 months). These
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findings support the fact that progestin treatment should
be recommended to patients who have a desire to preserve
fertility.
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In the current study, we analyzed the results of the
conservative treated patients. There were a few limitations
that should be indicated. First, there was a small number
of patients although the number was enough for a single
center study. Second, this was a retrospective study that
was based on clinical data. The strengths of the study are
that its relatively large sample size and analyses of the
outcomes. This work claims that medical treatment is a
feasible approach in early stage (G1 and no myometrial
invasion) endometrioid cancer and EIN patients with
comorbidities and fertility expectations. Also, a chance
should be given to the spontaneous pregnancies over ART.
Further prospective studies with a high patient population
are needed to make clear the treatment efficacy.
To the best of our knowledge, this is the largest single
center study with regards to the number of patients

with EIN. Fertility-sparing treatment of EAC and EIN
is a feasible approach, and a chance should be given
to spontaneous pregnancies together with artificial
reproductive techniques.
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